Hemodynamic and humoral effects of chronic antihypertensive treatment with fenquizone: importance of aldosterone response.
The effects of 1-year antihypertensive treatment with the diuretic fenquizone were evaluated in 16 patients with mild essential hypertension. During treatment with placebo, after 2, 4, 24, and 52 weeks of treatment we measured blood pressure, heart rate, forearm blood flow (FBF) and vascular resistance (FVR) at rest and after 10 minutes ischemia, and forearm venous distensibility. Subjects whose diastolic blood pressure after fenquizone was reduced at least 10% were classified as responders. On this basis, 56% of patients after 1 month and 68% after 1 year responded to fenquizone. Responders, in comparison to nonresponders, were characterized by a greater increase in FBF and a greater decrease in FVR. The reduction in diastolic blood pressure was significantly related to the fall in FVR whereas no correlation was found between blood pressure and venous compliance changes. Nonresponders had a PRA increase similar to that observed in responders but they showed a much greater increase in aldosterone, whose changes were inversely related to modifications of both FVR and blood pressure. Our results demonstrate that chronic therapy with fenquizone causes a reduction of FVR, and that nonresponders have an exaggerated rise in aldosterone. This observation further reinforces the hypothesis that factors influencing the secretion of aldosterone are important determinants of the antihypertensive mechanism of diuretics.
Costa
F V
FV
Cattedra di Terapia Medica Sistematica, Università di Bologna, Italy.
Borghi
C
C
Boschi
S
S
Mussi
A
A
Ambrosioni
E
E
D000328:Adult; D000450:Aldosterone / Q000097:blood*; D001794:Blood Pressure / Q000187:drug effects; D002908:Chronic Disease; D004232:Diuretics / Q000627:therapeutic use*; D005260:Female; D005542:Forearm / Q000098:blood supply; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D011799:Quinazolines / Q000627:therapeutic use*; D012039:Regional Blood Flow / Q000187:drug effects; D012083:Renin / Q000097:blood; D013449:Sulfonamides; D014655:Vascular Resistance / Q000187:drug effects
D004232:Diuretics; D011799:Quinazolines; D013449:Sulfonamides; D000450:Aldosterone; D012083:Renin; C007712:fenquizone